'Heparin' - From anticoagulant drug into the new biology

Glycoconjugate Journal

Volumn 17, Issue 7-9, 2000, Pages 597-605

  Lindahl, Ulf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antithrombin; Growth factors; Heparan sulfate; Heparin; Iduronic acid; Sulfotransferases

Indexed keywords

ANTICOAGULANT AGENT; HEPARAN SULFATE; HEPARIN;

ANTICOAGULATION; ENZYME SPECIFICITY; GENETIC POLYMORPHISM; METAMORPHOSIS; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTICOAGULANTS; AUTOBIOGRAPHY; CARBOHYDRATE SEQUENCE; HEPARIN; HEPARITIN SULFATE; HISTORY, 20TH CENTURY; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; SWEDEN;

EID: 0034444008     PISSN: 02820080     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011030711317     Document Type: Review

References (85)

1. 1 Gallagher JT, Walker A, Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides, Biochem J 230, 665-74 (1985).
2. 2 Lindahl U, Rodén L, In Glycoproteins - their composition, structure and function, edited by Gottschalk A, Vol. A (Elsevier, Amsterdam, 1972), pp. 491-517.
3. 3 Cifonelli JA, Dorfman A, The uronic acid of heparin, Biochem Biophys Res Commun 7, 41 (1962).
4. 4 Lindahl U, Further characterization of the heparin-protein linkage region, Biochim Biophys Acta 130, 368-82 (1966).
5. 5 Lindahl U, Axelsson O, Identification of iduronic acid as the major sulfated uronic acid of heparin, J Biol Chem 246, 74-82 (1970).
6. 6 Perlin AS, Mazurek M, Jaques LB, Kavanagh LW, A proton magnetic resonance spectral study of heparin, L-iduronic acid residues in commercial heparins, Carbohyd Res 7, 369-79 (1968).
7. 7 Casu B, Lindahl U, Structure and biological interactions of heparin and heparan sulfate. Adv Carbhohyd Chem Biochem (2000) in press.
8. 8 Helting T, Lindahl U, Occurrence and biosynthesis of β-glucuronidic linkages in heparin, J Biol Chem 246, 5442-7 (1971).
9. 9 Huckerby TN, Nieduszynski IA, Proton chemical-shift assignments in the n.m.r. spectra of heparan and heparin. Carbohyd Res 103, 141-5 (1982).
10. 10 Fransson L-Å, Rodén L, Structure of dermatan sulfate II. Characterization of products obtained by hyaluronidase digestion of dermatan sulfate, J Biol Chem 242, 4170-5 (1967).
11. 11 Jorpes JE, Gardell S, On heparin monosulfuric acid, J Biol Chem 176, 267-75 (1948).
12. 12 Cifonelli A, Reaction of heparitin sulfate with nitrous acid, Carbohyd Res 8, 233-42 (1968).
13. 13 Cifonelli JA, King J, Variable content of 2-acetoamido-2-deoxy-D-glucose and neutral sugars in mammalian heparins, Carbohyd Res 12, 391-402 (1970).
14. 14 Lindahl U, Bäckström G, Jansson L, Hallén A, Biosynthesis of heparin. Formation of sulfamino groups, J Biol Chem 248, 7234-41 (1973).
15. 15 Shively JE, Conrad HE, Formation of anhydrosugars in the chemical depolymerization of heparin, Biochemistry 15, 3932-42 (1976).
16. 16 Thunberg L, Bäckström G, Lindahl U, Further characterization of the antithrombin-binding sequence in heparin, Carbohyd Res 100, 393-410 (1982).
17. 17 Guo Y, Conrad HE, The disaccharide composition of heparins and heparan sulfates, Anal Biochem 176, 96-104 (1989).
18. 18 Maccarana M, Sakura Y, Tawada A, Yoshida K, Lindahl U, Domain structure of heparan sulfates from bovine organs, J Biol Chem 271, 17804-10 (1996).
19. 19 Gallagher JT, Structure-activity relationship of heparan sulphate, Biochem Soc Trans 25, 1206-9 (1997).
20. 20 Merry CL, Lyon M, Deakin JA, Hopwood JJ, Gallagher JT, Highly sensitive sequencing of the sulfated domains of heparan sulfate, J Biol Chem 274, 18455-62 (1999).
21. 21 Feyzi E, Saldeen T, Larsson E, Lindahl U, Salmivirta M, Age-dependent modulation of heparan sulfate structure and function, J Biol Chem 273, 13395-8 (1998).
22. 22 Lindahl B, Eriksson L, Lindahl U, Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease, Biochem J 306, 177-84 (1995).
23. 23 Lindahl B, Lindahl U, Amyloid-specific heparan sulfate from human liver and spleen, J Biol Chem 272, 26091-4 (1997).
24. 24 Safaiyan F, Lindahl U, Salmivirta M, Structural diversity of N-sulfated heparan sulfate domains, Biochemistry 39, 10823-30 (2000).
25. 25 van den Born J, Gunnarsson K, Bakker MAH, Kjellén L, Kusche-Gullberg M, Maccarana M, Berden JHM, Lindahl U, Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody, J Biol Chem 270, 31303-9 (1995).
26. 26 van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH, Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney, J Biol Chem 273, 12960-6 (1998).
27. 27 Venkataraman G, Shriver Z, Raman R, Sasisekharan R, Sequencing complex polysaccharides, Science 286, 537-42 (1999).
28. 28 Turnbull JE, Hopwood JJ, Gallagher JT, A strategy for rapid sequencing of heparan sulfate and heparin saccharides, Proc Natl Acad Sci USA 96, 2698-703 (1999).
29. 29 Vivès RR, Pye DA, Salmivirta M, Hopwood JJ, Lindahl U, Gallagher JT, Sequence analysis of heparan sulphate and heparin oligosaccharides, Biochem J 339, 767-73 (1999).
30. 30 Jansson L, Lindahl U, Evidence for the existence of a multichain proteoglycan of heparan sulphate, Biochem J 117, 699-702 (1970).
31. 31 Kjellén L, Pettersson I, Höök M, Cell-surface heparan sulfate: an intercalated membrane proteoglycan, Proc Natl Acad Sci USA 78, 5371-5 (1981).
32. 32 Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M, Functions of cell surface heparan sulfate proteoglycans, Annu Rev Biochem 68, 729-77 (1999).
33. 33 Iozzo RV, Matrix proteoglycans: from molecular design to cellular function, Annu Rev Biochem 67, 609-52 (1998).
34. 34 Robinson HC, Horner AA, Höök M, Ögren S, Lindahl U, A proteoglycan form of heparin and its degradation to single-chain molecules, J Biol Chem 253, 6687-93 (1978).
35. 35 Kjellén L, Pettersson I, Lillhager P, Steen M-L, Pettersson U, Lehtonen P, Karlsson T, Ruoslahti E, Hellman L, Primary structure of a mouse mastocytoma proteoglycan core protein, Biochem J 263, 105-13 (1989).
36. 36 Abildgaard U, Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 21, 89-91 (1968).
37. 37 Damus PS, Hicks M, Rosenberg RD, Anticoagulant action of heparin, Nature 246, 355-7 (1973).
38. 38 Lam LH, Silbert JE, Rosenberg RD, The separation of active and inactive forms of heparin, Biochem Biophys Res Commun 69, 570-7 (1976).
39. 39 Höök M, Björk I, Hopwood J, Lindahl U, Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin, FEBS Lett 66, 90-3 (1976).
40. 40 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC, Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration, Thromb Res 9, 575-83 (1976).
41. 41 Lindahl U, Bäckström G, Thunberg L, Leder IG, Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin, Proc Natl Acad Sci USA 77, 6551-5 (1980).
42. 42 Lindahl U, Thunberg L, Bäckström G, Riesenfeld J, Nordling K, Björk I, Extension and structural variability of the antithrombin-binding sequence in heparin, J Biol Chem 259, 12368-76 (1984).
43. 43 Bourin M-C, Lindahl U, Glycosaminoglycans and the regulation of blood coagulation, Biochem J 289, 313-30 (1993).
44. a activity, Biochem Biophys Res Commun 116, 492-9 (1983).
45. 45 Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM, Synthesis of thrombin-inhibiting heparin mimetics without side effects, Nature 398, 417-22 (1999).
46. 46 Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L, Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest 100, S67-75 (1997).
47. 47 Bjork I, Olson ST, Antithrombin. A bloody important serpin, Adv Exp Med Biol 425, 17-33 (1997).
48. 48 Pejler G, Danielsson Å, Björk I, Lindahl U, Nader HB, Dietrich CP, Structure and antithrombin-binding properties of heparin isolated from the clams Anomalocardia brasiliana and Tivela mactroides, J Biol Chem 262, 11413-21 (1987).
49. 49 Salmivirta M, Lidholt K, Lindahl U, Heparan sulfate - a piece of information, FASEB J 10, 1270-9 (1996).
50. 50 Parthasarathy N, Goldberg IJ, Sivaram P, Mulloy B, Flory DM, Wagner WD, Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase, J Biol Chem 269, 22391-6 (1994).
51. 51 Feyzi E, Lustig F, Fager G, Spillmann D, Lindahl U, Salmivirta M, Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain, J Biol Chem 272, 5518-24 (1997).
52. 52 Habuchi H, Suzuki S, Saito T, Tamura T, Harada T, Yoshida K, Kimata K, Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor, Biochem J 285, 805-13 (1992).
53. 53 Maccarana M, Casu B, Lindahl U, Minimal sequence in heparin/ heparan sulfate required for binding of basic fibroblast growth factor, J Biol Chem 268, 23898-905 (1993).
54. 54 Ishihara M, Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2, Glycobiology 4, 817-24 (1994).
55. 55 Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT, Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate, J Biol Chem 267, 10337-41 (1992).
56. 56 Kreuger J, Prydz K, Pettersson RF, Lindahl U, Salmivirta M, Characterization of fibroblast growth factor 1 binding heparan sulfate domain, Glycobiology 9, 723-9 (1999).
57. 57 Lyon M, Rushton G, Askari JA, Humphries MJ, Gallagher JT, Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin, J Biol Chem 275, 4599-606 (2000).
58. 58 Feyzi E, Trybala E, Bergström T, Lindahl U, Spillmann D, Structural requirement of heparan sulfate for interaction with Herpes simplex virus type 1 virions and isolated glycoprotein C, J Biol Chem 272, 24850-7 (1997).
59. 59 Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E, Timpl R, Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin, Embo J 18, 6240-8 (1999).
60. 60 Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC, Heparin structure and interactions with basic fibroblast growth factors, Science 271, 1116-20 (1996).
61. 61 Nurcombe V, Smart CE, Chipperfield H, Cool SM, Boilly B, Hondermarck H, The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates, J Biol Chem 275, 30009-18 (2000).
62. 62 Rapraeger AC, Krufka A, Olwin BB, Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation, Science 252, 1705-8 (1991).
63. 63 Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC, Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4, J Biol Chem 268, 23906-14 (1993).
64. 64 Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT, Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity, J Biol Chem 273, 22936-42 (1998).
65. 65 Pye DA, Gallagher JT, Monomer complexes of basic fibroblast growth factor and heparan sulfate oligosaccharides are the minimal functional unit for cell activation, J Biol Chem 274, 13456-61 (1999).
66. 66 Perrimon N, Bernfield M, Specificities of heparan sulphate proteoglycans in developmental processes, Nature 404, 725-8 (2000).
67. 67 Selleck SB, Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics, Trends Genet 206-12 (2000).
68. 68 Silbert JE, Biosynthesis of heparin. IV. N-deacetylation of a precursor glycosaminoglycan, J Biol Chem 242, 5153-7 (1967).
69. 69 Silbert JE, Biosynthesis of heparin. III. Formation of a sulfated glycosaminoglycan with a microsomal preparation from mast cell tumors, J Biol Chem 242, 5146-52 (1967).
70. 70 Lindahl U, Feingold DS, Rodén L, Biosynthesis of heparin, Trends Biochem Sci 11, 221-5 (1986).
71. 71 Lindahl U, In Heparin - chemical and biological properties, clinical applications, edited by Lane DA, Lindahl U, (Edward Arnold, London, 1989), pp. 159-89.
72. 72 Lindahl U, Kusche-Gullberg M, Kjellen L, Regulated diversity of heparan sulfate, J Biol Chem 273, 24979-82 (1998).
73. 73 Wei Z, Swiedler SJ, Ishihara M, Orellana A, Hirschberg CB, A single protein catalyzes both N-deacetylation and N-sulfation during the biosynthesis of heparan sulfate, Proc Natl Acad Sci USA 90, 3885-8 (1993).
74. 74 Eriksson I, Sandbäck D, Ek B, Lindahl U, Kjellén L, cDNA cloning and sequencing of mouse mastocytoma glucosaminyl N-deacetylase/N-sulfotransferase, an enzyme involved in the biosynthesis of heparin, J Biol Chem 269, 10438-43 (1994).
75. 75 Senay C, Lind T, Muguruma K, Tone Y, Kitagawa H, Sugahara K, Lidholt K, Lindahl U, Kusche-Gullberg M, The EXT1/EXT2 tumor suppressors; catalytic activities and role in heparan sulfate biosynthesis, EMBO Reports 1, 282-6 (2000).
76. 76 Pikas DS, Eriksson I, Kjellén L, Overexpression of different isoforms of glucosaminyl N-deacetylase/N-sulfotransferase results in distinct heparan sulfate N-sulfation patterns, Biochemistry 39, 4552-8 (2000).
77. 77 Aikawa J, Esko JD, Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNAc N-deacetylase/ N-sulfotransferase family, J Biol Chem 274, 2690-5 (1999).
78. 78 Li J-p, Hagner-McWhirter A, Kjellén L, Palgi J, Jalkanen M, Lindahl U, Biosynthesis of heparin/heparan sulfate. cDNA cloning and expression of D-glucuronyl C5-epimerase from bovine lung, J Biol Chem 272, 28158-63 (1997).
79. 79 Kobayashi M, Habuchi H, Yoneda M, Habuchi O, Kimata K, Molecular cloning and expression of Chinese hamster ovary cell heparansulfate 2-sulfotransferase, J Biol Chem 272, 13980-5 (1997).
80. 80 Rong J, Habuchi H, Kimata K, Lindahl U, Kusche-Gullberg M, Expression of heparan sulphate L-iduronyl 2-O-sulphotransferase in human kidney 293 cells results in increased D-glucuronyl 2-O-sulphation, Biochem J 346, 463-8 (2000).
81. 81 Habuchi H, Tanaka M, Habuchi O, Yoshida K, Suzuki H, Ban K, Kimata K, The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine, J Biol Chem 275, 2859-68 (2000).
82. 82 Liu J, Shworak NW, Sinay P, Schwartz JJ, Zhang L, Fritze LM, Rosenberg RD, Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities, J Biol Chem 274, 5185-92 (1999).
83. 83 Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG, A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry, Cell 99, 13-22 (1999).
84. 84 Ringvall M, Ledin J, Holmborn K, van Kuppevelt T, Ellin F, Eriksson I, Olofsson AM, Kjellén L, Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1, J Biol Chem 275, 25926-30 (2000).
85. 85 Forsberg E, Pejler G, Ringvall M, Lunderius C, Tomasini-Johansson B, Kusche-Gullberg M, Eriksson I, Ledin J, Hellman L, Kjellén L, Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme, Nature 400, 773-6 (1999).